These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 37221052)
1. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. Aktas O; Hartung HP; Smith MA; Rees WA; Fujihara K; Paul F; Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Cutter G; She D; Gunsior M; Cimbora D; Katz E; Cree BA; J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):757-768. PubMed ID: 37221052 [TBL] [Abstract][Full Text] [Related]
2. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106 [TBL] [Abstract][Full Text] [Related]
3. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C Front Immunol; 2021; 12():647618. PubMed ID: 33796113 [No Abstract] [Full Text] [Related]
4. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL; Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098 [TBL] [Abstract][Full Text] [Related]
5. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study. Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578 [TBL] [Abstract][Full Text] [Related]
6. Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa. Wang J; Wang J; Xie W; Liu J; Feng J; Wei W; Li M; Wu L; Wang C; Li R Int Immunopharmacol; 2023 Mar; 116():109761. PubMed ID: 36709595 [TBL] [Abstract][Full Text] [Related]
7. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Aktas O; Smith MA; Rees WA; Bennett JL; She D; Katz E; Cree BAC; Ann Neurol; 2021 May; 89(5):895-910. PubMed ID: 33724534 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study. Fujihara K; Kim HJ; Saida T; Misu T; Nagano Y; Totsuka N; Iizuka M; Kido S; Terata R; Okumura K; Hirota S; Cree BAC Mult Scler Relat Disord; 2023 Nov; 79():104938. PubMed ID: 37769428 [TBL] [Abstract][Full Text] [Related]
9. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Green AJ; Aktas O; Hartung HP; Lublin FD; Williams IM; Drappa J; She D; Cimbora D; Rees W; Smith M; Ratchford JN; Katz E; Cree BAC; Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33771837 [TBL] [Abstract][Full Text] [Related]
10. Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Lin TY; Schindler P; Grittner U; Oertel FC; Lu A; Motamedi S; Yadav SK; Duchow AS; Jarius S; Kuhle J; Benkert P; Brandt AU; Bellmann-Strobl J; Schmitz-Hübsch T; Paul F; Ruprecht K; Zimmermann HG Mult Scler Relat Disord; 2022 Nov; 67():104100. PubMed ID: 36049341 [TBL] [Abstract][Full Text] [Related]
11. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC; Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465 [TBL] [Abstract][Full Text] [Related]
12. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502 [TBL] [Abstract][Full Text] [Related]
13. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Cree BAC; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; Lublin FD; Drappa J; Barron G; Madani S; Ratchford JN; She D; Cimbora D; Katz E; Lancet; 2019 Oct; 394(10206):1352-1363. PubMed ID: 31495497 [TBL] [Abstract][Full Text] [Related]
14. Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum. Weinshenker BG; Wingerchuk DM; Green AJ; Bennett JL; Kim HJ; Pittock SJ; Fujihara K; Paul F; Cutter G; Marignier R; Aktas O; Hartung HP; She D; Smith M; Rees W; Patterson K; Cimbora D; Katz E; Cree BA Mult Scler; 2023 Jul; 29(8):945-955. PubMed ID: 37282545 [TBL] [Abstract][Full Text] [Related]
15. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial. Bennett JL; Aktas O; Rees WA; Smith MA; Gunsior M; Yan L; She D; Cimbora D; Pittock SJ; Weinshenker BG; Paul F; Marignier R; Wingerchuk D; Cutter G; Green A; Hartung HP; Kim HJ; Fujihara K; Levy M; Katz E; Cree BAC; EBioMedicine; 2022 Dec; 86():104321. PubMed ID: 36370634 [TBL] [Abstract][Full Text] [Related]
16. Combination of serum markers with optical coherence tomography angiography for evaluating neuromyelitis optica spectrum disorders and multiple sclerosis. Liu C; Zhou W; Sun X; Zhang X; Xiao H; Yang H; Lin H; Lu Y; Liu Z; Qiu W; Kermode AG; Yang X; Wang Y Mult Scler Relat Disord; 2024 May; 85():105478. PubMed ID: 38457885 [TBL] [Abstract][Full Text] [Related]
17. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Flanagan EP; Levy M; Katz E; Cimbora D; Drappa J; Mealy MA; She D; Cree BAC Mult Scler Relat Disord; 2022 Jan; 57():103352. PubMed ID: 35158461 [TBL] [Abstract][Full Text] [Related]
18. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Cree BA; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; Williams IM; Drappa J; She D; Cimbora D; Rees W; Ratchford JN; Katz E Mult Scler; 2021 Nov; 27(13):2052-2061. PubMed ID: 33538237 [TBL] [Abstract][Full Text] [Related]
19. Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder. Li Y; Liu Y; Zhao W; An X; Zhang F; Zhang TX; Liu Y; Du C; Zeng P; Yuan M; Zhang N; Zhang C J Neuroimmunol; 2023 Nov; 384():578218. PubMed ID: 37801952 [TBL] [Abstract][Full Text] [Related]
20. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder. Nie T; Blair HA CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]